IL162094A0 - Process for the manufacture of human mononuclear phagocytic leukocytes - Google Patents

Process for the manufacture of human mononuclear phagocytic leukocytes

Info

Publication number
IL162094A0
IL162094A0 IL16209402A IL16209402A IL162094A0 IL 162094 A0 IL162094 A0 IL 162094A0 IL 16209402 A IL16209402 A IL 16209402A IL 16209402 A IL16209402 A IL 16209402A IL 162094 A0 IL162094 A0 IL 162094A0
Authority
IL
Israel
Prior art keywords
manufacture
human mononuclear
mononuclear phagocytic
phagocytic leukocytes
leukocytes
Prior art date
Application number
IL16209402A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IL162094A0 publication Critical patent/IL162094A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
IL16209402A 2001-11-21 2002-11-21 Process for the manufacture of human mononuclear phagocytic leukocytes IL162094A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33178001P 2001-11-21 2001-11-21
PCT/IL2002/000930 WO2003044037A2 (en) 2001-11-21 2002-11-21 Process for the manufacture of human mononuclear phagocytic leukocytes

Publications (1)

Publication Number Publication Date
IL162094A0 true IL162094A0 (en) 2005-11-20

Family

ID=23295342

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16209402A IL162094A0 (en) 2001-11-21 2002-11-21 Process for the manufacture of human mononuclear phagocytic leukocytes
IL162094A IL162094A (en) 2001-11-21 2004-05-20 Process for the manufacture of a culture of activated human mononuclear phagocytic leukocytes

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162094A IL162094A (en) 2001-11-21 2004-05-20 Process for the manufacture of a culture of activated human mononuclear phagocytic leukocytes

Country Status (11)

Country Link
US (1) US8377692B2 (xx)
EP (1) EP1456355A4 (xx)
JP (2) JP2005519585A (xx)
KR (2) KR20100087781A (xx)
CN (1) CN1615357A (xx)
AU (1) AU2002353465B2 (xx)
CA (1) CA2467046C (xx)
IL (2) IL162094A0 (xx)
MX (1) MXPA04004813A (xx)
NZ (1) NZ533033A (xx)
WO (1) WO2003044037A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060210543A1 (en) * 2005-03-21 2006-09-21 Jonathan Leor Method of treating infarcted myocardium
US9220813B2 (en) * 2005-04-18 2015-12-29 Holy Cross Hospital, Inc. Cell therapy for limiting overzealous inflammatory reactions in tissue healing
CA2628712C (en) * 2005-11-07 2014-02-11 Amorcyte, Inc. Compositions and methods of vascular injury repair
US9034316B2 (en) * 2006-10-24 2015-05-19 Amorcyte, Llc Infarct area perfusion-improving compositions and methods of vascular injury repair
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
CN107595889A (zh) * 2008-09-12 2018-01-19 克里奥普拉斯低温生物有限公司 缺血性组织的细胞疗法
US8574902B2 (en) 2009-03-05 2013-11-05 Macrocure Ltd. Activated leukocyte composition and uses for wound healing
DK2403509T3 (da) * 2009-03-05 2013-09-16 Macrocure Ltd Aktiveret leukocytsammensætning
SG188266A1 (en) 2010-09-09 2013-04-30 Macrocure Ltd Activated leukocyte conditioned supernatant and uses for wound healing
ES2604356T3 (es) * 2011-12-14 2017-03-06 Yeda Research And Development Co. Ltd. Subpoblación de monocitos humanos para el tratamiento de lesiones del sistema nervioso central
EP2662085A1 (en) * 2012-05-11 2013-11-13 Humboldt-Universität zu Berlin Regulatory Macrophages and Their Uses
CN102703597B (zh) * 2012-06-20 2013-10-30 安徽信灵检验医学科技有限公司 血液白细胞分离液及其制作方法、真空采血管
US10188679B2 (en) 2013-05-22 2019-01-29 Yeda Research And Development Co. Ltd Human monocyte sub-population for treatment of eye diseases and disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086057A (en) 1976-07-28 1978-04-25 William Clinton Everett Ultrasonic disinfection system
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
JP3543869B2 (ja) 1995-03-07 2004-07-21 株式会社メニコン 培養皮膚およびその製造法
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
WO1999050391A1 (en) * 1998-03-30 1999-10-07 I.D.M. Immuno-Designed Molecules Stimulated monocyte derived cells, their preparation and uses
US6893462B2 (en) * 2000-01-11 2005-05-17 Regeneration Technologies, Inc. Soft and calcified tissue implants
US20030109583A1 (en) * 2001-07-25 2003-06-12 Raju Bore G. Administration of negamycin or deoxynegamycin for the treatment of bacterial infections

Also Published As

Publication number Publication date
NZ533033A (en) 2006-01-27
KR20100087781A (ko) 2010-08-05
EP1456355A2 (en) 2004-09-15
CN1615357A (zh) 2005-05-11
IL162094A (en) 2011-09-27
MXPA04004813A (es) 2004-08-11
CA2467046A1 (en) 2003-05-30
KR101001119B1 (ko) 2010-12-14
WO2003044037A3 (en) 2004-04-08
JP2010100653A (ja) 2010-05-06
AU2002353465A1 (en) 2003-06-10
US20050129663A1 (en) 2005-06-16
KR20040076860A (ko) 2004-09-03
AU2002353465B2 (en) 2008-10-16
WO2003044037A2 (en) 2003-05-30
US8377692B2 (en) 2013-02-19
JP5087094B2 (ja) 2012-11-28
CA2467046C (en) 2011-07-19
EP1456355A4 (en) 2005-05-25
JP2005519585A (ja) 2005-07-07

Similar Documents

Publication Publication Date Title
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
HUP0600332A2 (en) Aerosolized decongestants for the treatment of sinusitis
EP1427743A4 (en) SYNTHESIS OF PYRAZOLOPYRIMIDINES
HK1064296A1 (en) Preparation for the prophylaxis of restenosis
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
HUP0500851A3 (en) Process for the preparation of rosuvastatin
EP1390029A4 (en) PHENYLINDOLES FOR THE TREATMENT OF HIV INFECTION
HK1080361A1 (en) The use of compound in the preparation of medicaments for treating demyelinating diseases
EG22992A (en) Process for the preparation of urea
IL162094A0 (en) Process for the manufacture of human mononuclear phagocytic leukocytes
IL143106A (en) Process for the preparation of diphenylmethylthioacetamide
PL377464A1 (pl) Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
PL368532A1 (en) Method for the production of blister copper
PT1446107E (pt) Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
SG120874A1 (en) Process for the preparation of peptides
PL373627A1 (en) Process for the preparation of melamine
HUP0303025A3 (en) Process for the preparation of arylethanoldiamines
IL162770A0 (en) Process for the preparation methylsteroids of 7
IL164788A0 (en) Process for the preparation of 3-isochromanone
PL368905A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
HU0101713D0 (en) Process for the preparation of artificial blood
PL374911A1 (en) Process for the preparation of zaleplon
AU2002365654A8 (en) Treatment of diseases via the skin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed